神经科

以下为当前的临床试验。

按院区、状态和其他条件筛选该研究列表。

1. Cerebrospinal Fluid (CSF) Biomarkers for Prediction of Dementia

   Rochester, Minn., Jacksonville, Fla.

   To further investigate biomarkers in CSF as possible predictors for mild cognitive impairment and dementia

2. A Prospective Registry for Patients with REM Sleep Behavior Disorder and Polysomnographic REM Sleep without Atonia and Controls

   Rochester, Minn.

   The purpose of this study is to follow patients with REM sleep behavior disorder (RBD) over time and learn which types of RBD patients may be at risk of developing other diseases.

3. A Study to Evaluate Rozanolixizumab to Treat Patients with Generalized Myasthenia Gravis

   Rochester, Minn.

   The purpose of this study is to assess the safety, tolerability, and effectiveness of additional 6-week treatment cycles with Rozanolixizumab in study participants with generalized myasthenia gravis.

4. Acute Procedural Pain Treated With Remote Electrical Neuromodulation in Chronic Migraine Patients Receiving Onabotulinumtoxina

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the effectiveness of remote electrical neuromodulation with Nerivio ® (Theranica Bio-electronics, Ltd.) for treatment of acute procedural pain in patients receiving onabotulinumtoxinA for the treatment of chronic migraine.  

5. ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to evaluate sporadic (s-) and familial (f-) frontotemporal lobar degeneration (FTLD) patients and asymptomatic family members of f-FTLD patients, characterizing the cohorts longitudinally and informing clinical trial design.  FTLD is a neurodegenerative disorder of the nervous system which there are no approved treatments or cures.

   The study has two arms: a “longitudinal arm” involving a comprehensive assessment of clinical, functional, imaging, and biofluid data collection, and a “biofluid-focused arm” involving limited clinical data to accompany biospecimen collection.

6. A Study of Multicenter Outcomes in Pediatric Status Epilepticus

   Rochester, Minn.

   The purpose of this study is to develop a prospective status epilepticus registry among twelve tertiary care pediatric hospitals in the United States focused on standardizing status epilepticus outcome assessments.

7. Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

   Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purose of this study is to evaluate the effiectiveness, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory Primary Central Nervous System Lymphoma PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolimide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B). Mayo Clinic is only participatin gin Part B, and only in the MTR regimen. 

8. Image-based Mapping of Brain Tumors

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The purpose of this study is to combine MRI images with histologic and genetic analysis of cancer (from blood and tissue samples) to improve the overall accuracy of diagnosis and effectiveness of cancer treatment.

    

9. A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients with Recurrent Glioblastoma with Elevated Mutational Burden

   Jacksonville, Fla., Rochester, Minn., La Crosse, Wis., Scottsdale/Phoenix, Ariz., Eau Claire, Wis.

   The purpose of this study is to evaluate the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioblastoma that has come back (recurrent) and carries a high number of mutations. Cancer is caused by changes (mutations) to genes that control the way cells function. Tumors with high number of mutations may respond well to immunotherapy. Immunotherapy with monoclonal antibodies such as ipilimumab and nivolumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving ipilimumab and nivolumab may lower the chance of recurrent glioblastoma with high number of mutations from growing or spreading compared to usual care (surgery or chemotherapy).

10. Brain Tumor Repository

    Scottsdale/Phoenix, Ariz.

    The main objective of the Brain Tumor Repository is to allow access to coded patient data by researchers both inside and outside of the Mayo Clinic system so that important research questions can be answered.  Biospecimens will be collected and curated including excess fresh tissue collected during routine surgery, peripheral blood and urine at routine clinical followup times.

以下为当前的临床试验。

按院区、状态和其他条件筛选该研究列表。

1. Cerebrospinal Fluid (CSF) Biomarkers for Prediction of Dementia

   Rochester, Minn., Jacksonville, Fla.

   To further investigate biomarkers in CSF as possible predictors for mild cognitive impairment and dementia

2. A Prospective Registry for Patients with REM Sleep Behavior Disorder and Polysomnographic REM Sleep without Atonia and Controls

   Rochester, Minn.

   The purpose of this study is to follow patients with REM sleep behavior disorder (RBD) over time and learn which types of RBD patients may be at risk of developing other diseases.

3. A Study to Evaluate Rozanolixizumab to Treat Patients with Generalized Myasthenia Gravis

   Rochester, Minn.

   The purpose of this study is to assess the safety, tolerability, and effectiveness of additional 6-week treatment cycles with Rozanolixizumab in study participants with generalized myasthenia gravis.

4. Acute Procedural Pain Treated With Remote Electrical Neuromodulation in Chronic Migraine Patients Receiving Onabotulinumtoxina

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the effectiveness of remote electrical neuromodulation with Nerivio ® (Theranica Bio-electronics, Ltd.) for treatment of acute procedural pain in patients receiving onabotulinumtoxinA for the treatment of chronic migraine.  

5. ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to evaluate sporadic (s-) and familial (f-) frontotemporal lobar degeneration (FTLD) patients and asymptomatic family members of f-FTLD patients, characterizing the cohorts longitudinally and informing clinical trial design.  FTLD is a neurodegenerative disorder of the nervous system which there are no approved treatments or cures.

   The study has two arms: a “longitudinal arm” involving a comprehensive assessment of clinical, functional, imaging, and biofluid data collection, and a “biofluid-focused arm” involving limited clinical data to accompany biospecimen collection.

6. A Study of Multicenter Outcomes in Pediatric Status Epilepticus

   Rochester, Minn.

   The purpose of this study is to develop a prospective status epilepticus registry among twelve tertiary care pediatric hospitals in the United States focused on standardizing status epilepticus outcome assessments.

7. Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

   Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purose of this study is to evaluate the effiectiveness, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory Primary Central Nervous System Lymphoma PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolimide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B). Mayo Clinic is only participatin gin Part B, and only in the MTR regimen. 

8. Image-based Mapping of Brain Tumors

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The purpose of this study is to combine MRI images with histologic and genetic analysis of cancer (from blood and tissue samples) to improve the overall accuracy of diagnosis and effectiveness of cancer treatment.

    

9. A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients with Recurrent Glioblastoma with Elevated Mutational Burden

   Jacksonville, Fla., Rochester, Minn., La Crosse, Wis., Scottsdale/Phoenix, Ariz., Eau Claire, Wis.

   The purpose of this study is to evaluate the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioblastoma that has come back (recurrent) and carries a high number of mutations. Cancer is caused by changes (mutations) to genes that control the way cells function. Tumors with high number of mutations may respond well to immunotherapy. Immunotherapy with monoclonal antibodies such as ipilimumab and nivolumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving ipilimumab and nivolumab may lower the chance of recurrent glioblastoma with high number of mutations from growing or spreading compared to usual care (surgery or chemotherapy).

10. Brain Tumor Repository

    Scottsdale/Phoenix, Ariz.

    The main objective of the Brain Tumor Repository is to allow access to coded patient data by researchers both inside and outside of the Mayo Clinic system so that important research questions can be answered.  Biospecimens will be collected and curated including excess fresh tissue collected during routine surgery, peripheral blood and urine at routine clinical followup times.